Glenmark Pharmaceuticals Ltd Q4 FY2025 Concall Summary

Key Takeaways

• Guidance anchors the story: Management guided FY26 revenue growth of 10–12% and EBITDA margins of 19–20%, with ₹300–400 cr free cash flow, all excluding any IGI licensing deal.
• India reported a weak quarter but secondary sales tell a different story: Q4 India formulation sales grew just 0.4% YoY as acute respiratory stayed soft, diabetes eroded, and low-margin brands were discontinued, yet IQVIA secondary sales grew 10.3% in Q4 and 12% MAT March versus IPM's 6.9% and 7.7%.
• The ISB 2001 licensing deal is the single biggest catalyst: Management called a deal "transformational" and said it would "overshadow anything else," with advanced discussions underway and an outcome expected "pretty quickly"; the deal would cover IGI's ~\$70 mn annual burn for at least three years.
• U.S. margin recovery is a launch-timing story: North America declined 5.4% YoY with suppressed margins because launches were back-ended to Q4; the impact of those launches plus Flovent 44 MCG approval expected end-Q2 and nasal spray launches in H2 should lift margins from Q1.
• What to watch next quarter: Whether the ISB 2001 licensing deal closes and on what terms, the pace of India diabetes portfolio stabilization as Lirafit supply resolves, and any FDA inspection news on Monroe or Goa.

India Business: Reported Weakness, Underlying Strength

• Acute respiratory dragged headline growth: The acute respiratory market saw low seasonal pickup, which combined with a 10% decline in the diabetes portfolio and discontinuation of select noncore low-margin hospital and trade generic brands to produce just 0.4% YoY reported growth.
• Secondary sales far outpaced reported: IQVIA data showed Glenmark's India formulations grew 10.3% in Q4 and 12% MAT March, roughly 1.5x the IPM growth rates of 6.9% and 7.7%, implying the reported number reflects channel destocking and portfolio cleanup rather than demand weakness.
• Chronic respiratory is the bright spot: The chronic respiratory portfolio grew over 20% in Q4, sustaining momentum that management expects to continue.
• Diabetes is in transition, not structural decline: Two molecules, remogliflozin and teneligliptin, once contributed ~60% of the diabetes franchise but became unsustainable after dapagliflozin and sitagliptin went generic. The company is transitioning to Lirafit (liraglutide), sitagliptin, and empagliflozin, with a semaglutide launch also expected to help stabilize the franchise, though the rebuild will take time.
• Lirafit supply constrained growth: Lirafit has gained good doctor traction but growth is capped by supply challenges from the partner; management hopes for resolution in Q1.

Glenn Saldanha: "At one point, these 2 products contributed almost 60% of the diabetes franchise, just to tell you how big they were, these 2 molecules. So the erosion that we saw was not -- we were struggling to sustain that."

ISB 2001 and IGI: The Transformational Catalyst

• ISB 2001 is in advanced partnering discussions: Management is in discussions with multiple big pharma partners and anticipates a positive outcome "pretty quickly," describing a deal as "transformational for Glenmark" that "will overshadow anything else that we are doing in the near term."
• Clinical progress supports deal momentum: ISB 2001 received U.S. FDA Fast Track designation in May 2025 for relapsed refractory multiple myeloma, completed Phase I dose escalation enrollment in March, dosed the first patient in dose expansion in April, and will have an oral presentation at ASCO following an ASH oral presentation in December 2024 on data from 20 heavily pretreated patients.
• A deal would make IGI self-sustaining: Management stated that a licensing deal would more than cover IGI's expenditure for at least the next three years (~\$70 mn/year), eliminating the need for further Glenmark funding, with the eventual vision of an IGI IPO to provide independent access to capital.
• Envafolimab adds a second IGI asset in play: First market launch is expected in FY26, and a global multicenter Phase III study is planned in FY26 for neoadjuvant, adjuvant, and NSCLC indications.

Glenn Saldanha: "We think a deal for 2001 will really be transformational for Glenmark. And it will overshadow anything else that we are doing in the near term. So I think you should see some visibility around a licensing deal pretty quickly."

U.S. Business: Launches Are the Margin Lever

• Q4 decline was a launch-timing gap: North America revenue declined 5.4% YoY because most launches were back-ended toward Q4, so their full impact was not visible in the quarter, and margins have been suppressed by the lack of new product flow.
• The launch pipeline is now filling: In-licensed products including mixed amphetamines launched in Q4 and are beginning to gain share; generic Flovent 44 MCG approval is expected toward the end of Q2 FY26, with the 110 MCG filing in Q2 and 220 MCG filing toward end-H2; nasal spray launches are expected in H2 FY26; and one additional MDI filing is planned in Q2 outside of the Flovent strengths, totaling three MDI filings this year plus two or three nasal spray filings.
• Flovent is a high-barrier opportunity: Management emphasized that Flovent is an extremely difficult product that most of the industry has struggled to develop, implying limited competition when approvals come through.
• Margin recovery expected from Q1: Launches made in Q4 should start improving the U.S. margin profile from Q1, with RYALTRIS called out as a big margin driver alongside Flovent and nasal sprays.

Glenn Saldanha: "Flovent is an extremely difficult product, okay? I mean I think a lot -- most of the industry has struggled to develop this product."

Europe and ROW: The Steady Growth Engines

• Europe delivered ~20% growth: Branded business drove growth across all key markets, with Central and Eastern Europe posting double-digit growth across all markets and the branded respiratory portfolio sustaining momentum.
• ROW growth understated by forex: Reported ROW growth of 4.9% was impacted by adverse currency movements; on a constant-currency basis, ROW grew over 10% in FY25 and is expected to accelerate further with big launches and RYALTRIS contributing in 10–12 markets where it has not yet launched.
• RYALTRIS is approaching a milestone: Sales are expected to cross \$100 mn in FY26, with additional launches in 10–12 markets over the next few quarters and China approval expected sometime in FY26 via partner Grand Pharmaceutical.
• WINLEVI and respiratory launches expand the footprint: WINLEVI received U.K. MHRA approval in Q4 with launch planned in FY26, while other European market approvals are awaited; in LatAm, the first generic salmeterol/fluticasone MDI launched in Brazil in Q1 FY25 and is gaining share.

Manufacturing and Regulatory: Three Plants, Three Timelines

• Monroe plant is closest to resolution: Management met with the FDA and believes an inspection should come "anytime"; the current focus is on injectable lines and utilities, with the goal of getting the plant cleared and reinitiating injectable manufacturing before considering expansion into other areas.
• Goa plant is in the same queue: A meeting with the FDA has been completed and the company is waiting for an inspection, with no further specifics on timing.
• Pithampur plant has no near-term commercial impact: Discussions with the FDA are ongoing but no launches are tied to Pithampur, so there is no immediate impact on the U.S. business, though no timeline or outcome was provided.
• IGI facility closure is a cost action, not a setback: IGI announced plans to cease all CMC development and clinical supply manufacturing at La Chaux-de-Fonds, Switzerland, moving to a global CDMO network, with an associated exceptional loss booked in the quarter.

Guidance, Cash Flow, and the IGI Wildcard

• FY26 guidance excludes any IGI deal: Revenue growth of 10–12% and EBITDA margins of 19–20% are based on the core business only; management said it feels comfortable with these numbers.
• Free cash flow guided at ₹300–400 cr: This is post-interest and post-dividend, with interest expense expected to come a little lower in the coming year and R&D spend roughly around 6–7% of revenue.
• An IGI licensing deal would transform the financial profile: The deal would more than cover IGI's ~\$70 mn annual expenditure for at least three years, removing a significant cash drain from the consolidated business and potentially funding the path to an IGI IPO.
• An analyst meet in July 2025 will provide region-wise and business-wise granular guidance, including more detail on margin drivers.

Glenn Saldanha: "From the licensing deal at least the next 3 years of IGI expenditure will get more than covered."

Guidance & Commitments

Key Metrics